Crazy Volume Spikes for: Incyte Corporation (INCY)

The stock has "Buy" rating by Needham on Friday, March 24. Iclusig also faces intense competition. Gabelli began coverage on Incyte in a research report on Monday, April 10th. On Tuesday, August 18 the stock rating was maintained by Cowen & Co with "Outperform". The stock's average target of $111.11 is -11.35% below today's ($125.34) share price.

4/17/2017-Piper Jaffray Companies Reiterated Rating of Overweight. Stock has got OUTPERFORM rating from 13 analysts of Thomson Reuters, 16 analysts given HOLD rating to the stock and 2 given UNDERPERFORM rating. The stock gained a consensus recommendation of 1.22 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. Royal Bank of Canada lifted their price objective on Incyte from $123.00 to $138.00 and gave the company an "outperform" rating in a research report on Wednesday, February 15th. The analysts offering Earnings Estimates for the company were believing that Incyte Corporation (INCY) could bring EPS of $0.13/share.

Incyte Co. has a 52-week low of $68.03 and a 52-week high of $153.15. The firm's 50-day moving average is $139.53 and its 200 day moving average is $114.02. GRYSKA DAVID W also sold $5.73 million worth of Incyte Corporation (NASDAQ:INCY) on Monday, April 10. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.14 by $0.09. Incyte had a net margin of 14.71% and a return on equity of 50.38%. INCY generated revenue of $300.83 Million in the same quarter, one year ago. On average, analysts forecast that Incyte will post $0.18 EPS for the current fiscal year. The business's revenue was up 33.9% compared to the same quarter past year.

Shares outstanding are recorded as 203.82 M and total shares floated are 202.80 M. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 3.60. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & global copyright and trademark law. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/04/17/incyte-co-incy-given-average-rating-of-buy-by-brokerages.html. $6.02 million worth of Incyte Corporation (NASDAQ:INCY) shares were sold by FRIEDMAN PAUL A. BROOKE PAUL A sold $2.96M worth of stock. The stock was sold at an average price of $113.55, for a total value of $1,332,963.45. Seven Bridges Advisors LLC now owns 1,867 shares of the biopharmaceutical company's stock worth $176,000 after buying an additional 398 shares in the last quarter. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

In other Incyte news, Director Jean Jacques Bienaime acquired 1,000 shares of Incyte stock in a transaction that occurred on Friday, April 7th. INCY has P/E (Price to Earnings ttm) value of 234.33, Forward P/E of 130.78, P/C (Price to cash per share) of 31.78 and Price to Free Cash Flow (P/FCF) value of 139.27. Following the completion of the purchase, the director now directly owns 2,177 shares of the company's stock, valued at approximately $303,647.96. The disclosure for this sale can be found here. The stock's average target of $51 is 32.30% above today's ($38.55) share price. HighTower Advisors LLC now owns 13,226 shares of the biopharmaceutical company's stock worth $1,244,000 after buying an additional 159 shares during the last quarter. Institutional investors own 92.62% of the company's stock. Fisher Asset Management LLC increased its position in Incyte by 0.7% in the third quarter.

In the last Quarter, Incyte Corporation (INCY) reported its Actual EPS of $0.05/share. Finally, Pinnacle Associates Ltd. bought a new position in shares of Incyte during the fourth quarter worth approximately $212,000. They expect $-0.74 earnings per share, down 716.67% or $0.86 from last year's $0.12 per share. Grandfield & Dodd LLC raised its stake in Incyte by 4.4% in the third quarter. The stock increased 1.84% or $0.9 during the last trading session, reaching $49.7. Nationwide Fund Advisors now owns 117,435 shares of the biopharmaceutical company's stock valued at $11,073,000 after buying an additional 37,500 shares during the last quarter.

  • Zachary Reyes